Stephen Mahoney is President, Chief Executive Officer of Viridian Therapeutics, Inc. (VRDN). The company reported total compensation of $6,776,249 for fiscal year 2025.
| Salary | $700,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $1,058,098 |
| Option awards | $4,381,713 |
| Non-equity incentive plan | $630,000 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $6,438 |
| Total | $6,776,249 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Viridian Therapeutics, Inc. filed April 17, 2026, accession 0001193125-26-160344.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President, Chief Executive Officer | $700,000 | $0 | $1,058,098 | $4,381,713 | $630,000 | $0 | $6,438 | $6,776,249 |
| FY2024 | President, Chief Executive Officer | $650,000 | $0 | $0 | $0 | $464,750 | $0 | $2,704 | $1,117,454 |
| FY2023 | President, Chief Executive Officer | $112,847 | $63,762 | $0 | $12,302,728 | $0 | $0 | $184 | $12,479,521 |
Totals as disclosed in each year's own compensation disclosure for Viridian Therapeutics, Inc..
| Peer-group chief executive median | $6,617,979 |
|---|---|
| Difference from that median | $158,270 |
| Percentile within the disclosed peer group | 56th |
| Peers with a disclosed figure | 8 |
Medians and percentiles are computed across the peer group Viridian Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Stephen Mahoney this page | President, Chief Executive Officer | $6,776,249 |
| Radhika Tripuraneni | Chief Medical Officer | $4,080,466 |
| Thomas Beetham | Chief Operating Officer | $3,761,182 |
| Seth Harmon | Chief Financial Officer | $2,642,779 |
| Jennifer Tousignant | Chief Legal Officer | $2,351,915 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Viridian Therapeutics, Inc. compensation brief.
Stephen Mahoney's compensation sits inside Viridian Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.